Drug Discovery World

OCTOBER 4, 2022

New York-based Oligomerix is an emerging clinical-stage biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterised by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD) to Alzheimer’s disease (AD).

Disease 130

Disease Small Molecule Compound Screening Clinical Development 130

Drug Target Review

NOVEMBER 1, 2023

I work in the Centre for Cancer Drug Discovery (CCDD) at The Institute of Cancer Research in London, which is an academic drug discovery centre. The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

Drug Discovery World

JANUARY 26, 2023

“Virtual trials, including at-home check-ups, remote monitoring and assessments and direct-to-patient drug distribution, are just some of the ways in which R&D leaders can decentralise the clinical trial process to cut drug development timelines.

Clinical Trials 246

Clinical Trials Drugs Trials Therapies 246